CenterBook Partners LP Buys 3,039 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

CenterBook Partners LP increased its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIOFree Report) by 43.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,054 shares of the medical research company’s stock after acquiring an additional 3,039 shares during the quarter. CenterBook Partners LP’s holdings in Bio-Rad Laboratories were worth $3,246,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of BIO. J.P. Morgan Private Wealth Advisors LLC bought a new position in Bio-Rad Laboratories during the third quarter worth $3,489,000. Banque Cantonale Vaudoise increased its holdings in Bio-Rad Laboratories by 25.0% in the 3rd quarter. Banque Cantonale Vaudoise now owns 375 shares of the medical research company’s stock valued at $135,000 after buying an additional 75 shares during the period. Massachusetts Financial Services Co. MA bought a new stake in Bio-Rad Laboratories in the 3rd quarter valued at $116,036,000. First Eagle Investment Management LLC increased its holdings in Bio-Rad Laboratories by 139.8% in the 3rd quarter. First Eagle Investment Management LLC now owns 458 shares of the medical research company’s stock valued at $164,000 after buying an additional 267 shares during the period. Finally, Janney Montgomery Scott LLC increased its holdings in Bio-Rad Laboratories by 119.0% in the 3rd quarter. Janney Montgomery Scott LLC now owns 4,743 shares of the medical research company’s stock valued at $1,701,000 after buying an additional 2,577 shares during the period. Institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Stock Down 0.7 %

NYSE BIO traded down $1.98 on Friday, hitting $287.02. 210,323 shares of the company were exchanged, compared to its average volume of 201,676. The firm has a 50 day moving average of $294.22 and a two-hundred day moving average of $313.04. The company has a quick ratio of 4.89, a current ratio of 6.57 and a debt-to-equity ratio of 0.13. Bio-Rad Laboratories, Inc. has a 1-year low of $261.59 and a 1-year high of $431.79.

Bio-Rad Laboratories (NYSE:BIOGet Free Report) last issued its quarterly earnings results on Tuesday, May 7th. The medical research company reported $2.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.04 by $0.25. The business had revenue of $610.82 million for the quarter, compared to the consensus estimate of $619.09 million. Bio-Rad Laboratories had a negative net margin of 12.37% and a positive return on equity of 3.59%. The firm’s quarterly revenue was down 9.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.34 EPS. On average, research analysts expect that Bio-Rad Laboratories, Inc. will post 10.4 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. UBS Group lowered their price target on shares of Bio-Rad Laboratories from $420.00 to $385.00 and set a “buy” rating on the stock in a report on Wednesday, May 8th. StockNews.com upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Tuesday, May 28th. Royal Bank of Canada reduced their target price on shares of Bio-Rad Laboratories from $484.00 to $480.00 and set an “outperform” rating on the stock in a research note on Friday, February 16th. Citigroup downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and reduced their target price for the company from $400.00 to $365.00 in a research note on Wednesday, April 3rd. Finally, Jefferies Financial Group restated a “hold” rating and issued a $315.00 target price (down previously from $440.00) on shares of Bio-Rad Laboratories in a research note on Monday, June 3rd. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $436.67.

Get Our Latest Report on Bio-Rad Laboratories

Bio-Rad Laboratories Profile

(Free Report)

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.

Recommended Stories

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIOFree Report).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.